Want to see SE:PILA full AI Analyst Report?
Top Page
PILA PHARMA AB
(PILA)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr1.50
▼(-31.82% Downside)
Action:Reiterated
Date:09/24/26
The score is primarily held down by weak financial performance—shrinking TTM revenue, large ongoing losses, and persistent negative free cash flow indicating continued reliance on external funding. Technical indicators are neutral to mildly supportive (positive MACD and price above longer-term averages), but they are not strong enough to offset the fundamental cash-burn profile. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Zero Financial Debt
The absence of reported debt reduces near-term interest and refinancing pressure, giving PILA greater financial flexibility than a similarly loss-making company with leverage. This can preserve strategic options while it advances development, although it does not eliminate the need for future funding.
Negative Factors
Sharp Revenue Contraction
A steep decline from an already low revenue base signals that PILA has not established consistent commercial or other recurring revenue. Without improving revenue, the company remains dependent on financing or future development success to support operations and fund its pipeline.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Financial Debt
The absence of reported debt reduces near-term interest and refinancing pressure, giving PILA greater financial flexibility than a similarly loss-making company with leverage. This can preserve strategic options while it advances development, although it does not eliminate the need for future funding.
Read all positive factors
PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr74.46M
Dividend YieldN/A
Average Volume (3M)111.11K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth-71.19%
EPS Growth-23.18%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding45,682,120
10 Day Avg. Volume73,560
30 Day Avg. Volume111,110
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)4.82
Price to Sales (P/S)63.25
P/FCF Ratio-7.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
PILA PHARMA AB Business Overview & Revenue Model
Company Description
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treati...
How the Company Makes Money
As a clinical-stage pharmaceutical company, PILA PHARMA AB’s ability to generate recurring commercial revenue depends on successful drug development and subsequent commercialization or partnering. Specific, company-reported details on current reve...
PILA PHARMA AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.74K | 1.13M | 775.00K | 1.46M | 1.88M | 719.23K |
| Gross Profit | -5.95M | -6.82M | -8.12M | 1.46M | 1.88M | 680.94K |
| EBITDA | -6.71M | -15.92M | -10.11M | -8.81M | -26.76M | -17.16M |
| Net Income | -16.77M | -16.86M | -11.24M | -9.93M | -26.78M | -17.21M |
Balance Sheet | ||||||
| Total Assets | 16.86M | 16.22M | 6.22M | 8.46M | 10.89M | 31.81M |
| Cash, Cash Equivalents and Short-Term Investments | 3.26M | 15.90M | 4.89M | 5.95M | 7.24M | 28.21M |
| Total Debt | 0.00 | 0.00 | 0.00 | 773.08K | 0.00 | 0.00 |
| Total Liabilities | 748.00K | 1.43M | 963.00K | 1.79M | 1.36M | 1.51M |
| Stockholders Equity | 16.11M | 14.78M | 5.26M | 6.66M | 9.53M | 30.30M |
Cash Flow | ||||||
| Free Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Operating Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 22.97M | 20.19M | 6.76M | 3.56M | -11.88M | 35.67M |
PILA PHARMA AB Technical Analysis
Negative
2.20
Price Trends
1.64
Positive
1.50
Positive
1.55
Positive
Market Momentum
>-0.01
Positive
46.13
Neutral
41.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.64, and above the 200-day MA of 1.55, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.13 is Neutral, neither overbought nor oversold. The STOCH value of 41.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PILA.
PILA PHARMA AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr65.79M | -2.17 | -177.45% | ― | ― | 0.22% | |
47 Neutral | kr93.47M | -1.77 | -62.21% | ― | ― | 58.15% | |
45 Neutral | kr74.46M | -4.09 | -108.78% | ― | -71.19% | -23.18% | |
42 Neutral | kr83.04M | -1.88 | -2775.09% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
SE:PILA
PILA PHARMA AB
1.66
-0.66
-28.45%
SE:ONCOZ
OncoZenge AB
3.60
-1.40
-27.96%
SE:ACE
Ascelia Pharma AB
0.86
-2.24
-72.34%
SE:MODTX
Modus Therapeutics Holding AB
0.39
-0.07
-15.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.